lundi 14 juin 2021

Humacyte to Present at the 37th Annual J.P. Morgan Healthcare Conference

Par Rédaction , dans Communiqués , le 11 janvier 2019

Monday, January 7th 2019 at 12:30pm UTC

RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)– Humacyte, an innovator in biotechnology and regenerative medicine,
announced today that Jeffrey Lawson, M.D., Ph.D., President and Chief
Executive Officer, will present a company overview at the 37th Annual
J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San
Francisco, California, on Tuesday, January 8, 2019 at 9:00 a.m. Pacific


Humacyte, Inc., a privately held company founded by Dr. Laura E.
Niklason, M.D., Ph.D., in 2004, is a medical research, discovery and
development company with clinical and pre-clinical stage investigational
products. Humacyte is primarily focused on developing and
commercializing a proprietary novel technology based on human
tissue-based products for key applications in regenerative medicine and
vascular surgery. The company uses its innovative, proprietary platform
technology to engineer human, extracellular matrix-based tissues that
can be shaped into tubes, sheets, or particulate conformations, with
properties similar to native tissues. These are being developed for
potential use in many specific applications, with the goal to
significantly improve treatment outcomes for many patients, including
those with vascular disease and those requiring hemodialysis. The
company’s proprietary technologies are designed to create off-the-shelf
products that, once approved, can be utilized in any patient. The
company web site is


Douglas Blankenship
[email protected]

Westwicke Partners
Mike Piccinino
[email protected]

ICR, PR for Humacyte
Nirav Suchak
[email protected]

Source: Humacyte Inc.

Étiquettes : , , , , , , , ,